- Conditions
- Hepatocellular Carcinoma, Hepatoma, Cholangiocarcinoma, Liver Metastases
- Interventions
- Endoscopy ultrasound
- Procedure
- Lead sponsor
- Central Texas Veterans Health Care System
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Temple, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 747
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Liver Cancer
- Interventions
- bevacizumab, dexamethasone, floxuridine, protein expression analysis, flow cytometry, immunoenzyme technique, immunohistochemistry staining method, immunologic technique, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging
- Biological · Drug · Genetic + 2 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2024
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Not listed
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Prednisone
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Advanced Hepatocellular Carcinoma, Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasms, Hepatic Cancer, Hepatic Carcinoma
- Interventions
- H3B-6527
- Drug
- Lead sponsor
- H3 Biomedicine Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Newport Beach, California • Orange, California + 11 more
- Conditions
- Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
- Interventions
- Atezolizumab, Bevacizumab, Biospecimen Collection, Computed Tomography, Durvalumab, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy, Tremelimumab
- Biological · Procedure · Other + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 138
- States / cities
- Berkeley, California • Cameron Park, California • Fremont, California + 108 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Cabozantinib tablets, Placebo tablets
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 707 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 22
- States / cities
- Corona, California • Los Angeles, California • San Diego, California + 17 more
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE)
- Drug · Procedure
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 21
- States / cities
- Aurora, Colorado • Gainesville, Florida • Orlando, Florida + 16 more
- Conditions
- Hepatitis B Virus Infection
- Interventions
- Flavonoid, Tenofovir
- Drug
- Lead sponsor
- Trieu, Nguyen Thi, M.D.
- Individual
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 1
- States / cities
- Wilmington, Delaware
- Conditions
- Hepatocellular Carcinoma, Liver Neoplasms
- Interventions
- ThermoDox
- Drug
- Lead sponsor
- Imunon
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Manhasset, New York
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Biopsy, Computed Tomography, Gallium Ga 68 Gozetotide, Magnetic Resonance Imaging, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Zanzalintinib, Durvalumab, Tremelimumab
- Drug
- Lead sponsor
- Anwaar Saeed
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Pittsburgh, Pennsylvania • Houston, Texas • San Antonio, Texas
- Conditions
- Gastric Cancers
- Interventions
- Not listed
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- Not listed
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2030
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Carcinoma, Hepatocellular, Liver Cancer, Liver Cirrhosis, Hepatitis B
- Interventions
- GALAD, Liver Ultrasound with or without AFP
- Diagnostic Test
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 5,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2034
- U.S. locations
- 19
- States / cities
- Los Angeles, California • Redwood City, California • Roseville, California + 14 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- DCR-MYC
- Drug
- Lead sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Boston, Massachusetts • San Antonio, Texas
- Conditions
- Hepatocellular Carcinoma, Cirrhosis
- Interventions
- Usual care, Opt-out, Opt-out + Incentive
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 615 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hepatocellular Carcinoma
- Interventions
- mapatumumab, sorafenib
- Biological · Drug
- Lead sponsor
- Human Genome Sciences Inc., a GSK Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 3 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Brivanib, Brivanib Placebo, TACE Therapy
- Drug · Other · Procedure
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 734 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Diego, California • The Bronx, New York + 4 more
- Conditions
- Advanced Adult Hepatocellular Carcinoma
- Interventions
- Cabozantinib
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Ann Arbor, Michigan • Dallas, Texas
- Conditions
- Hepatocellular Carcinoma, Liver Cancer
- Interventions
- Durvalumab, Zanzalintinib
- Drug
- Lead sponsor
- Amit Mahipal
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Pembrolizumab, Placebo
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 959 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 24
- States / cities
- Gilbert, Arizona • Tucson, Arizona • Duarte, California + 18 more
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Interventions
- oxaliplatin, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Advanced Adult Hepatocellular Carcinoma
- Interventions
- Dalantercept plus sorafenib
- Drug
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Westwood, Kansas • Boston, Massachusetts + 4 more
- Conditions
- Hepatocellular Carcinoma, Cancer of Liver
- Interventions
- PXS-5505 and Atezolizumab and Bevacizumab
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, New York